Current Tropical Medicine Reports

, Volume 5, Issue 3, pp 133–137 | Cite as

Update of Hepatitis C in Colombia

  • Federico HinestrosaEmail author
  • Juan Ignacio Marín
  • Octavio Muñoz Maya
  • Oscar Santos
  • Juan Carlos Restrepo
Tropical Diseases in Colombia (A Restrepo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Tropical Diseases in Colombia


Purpose of Review

The goal is to describe the epidemiology, disease burden and detection, available therapies, and current challenges to access care for people with chronic hepatitis C infection in Colombia.

Recent Findings

There are no detailed statistics about the prevalence of HCV in Colombia; nonetheless, majority of patients with hepatitis C are infected with genotype 1 and having received blood products before 1996 represents the main risk factor. The use of intravenous drugs has started to be recognized as a population at risk that is in increment. Direct-acting antivirals became available in 2016 in Colombia thanks to a centralized purchase program with the Pan American Health Organization.


There are well-established guidelines for the use of available antivirals for all disease stages and genotypes and sustained virologic response (SVR) rates are 95 to 100%. Underdiagnosis, access and linkage to care, and disease stigmatization have contributed to a low number of patients that have actually completed their therapy.


Hepatitis C HCV Colombia South America Direct-acting antiviral DAA 


Compliance with Ethical Standards

Conflict of Interest

Federico Hinestrosa reports grants, as well as research and a speaker honorarium from Gilead Sciences, grants, as well as research and a speaker honorarium from Abbvie Inc., grants from Brystol Myers Squibb for research, a speaker honorarium from Merck Sharp & Dohme, and a speaker honorarium from Janssen Pharmaceuticals, outside the submitted work. Juan Ignacio Marín, Octavio Muñoz Maya, Oscar Santos, and Juan Carlos Restrepo declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMedGoogle Scholar
  2. 2.
    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  3. 3.
    Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353–63.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis. 2016. Available from
  8. 8.
    Hoyos A. Epidemiologia de la hepatitis C en Colombia. Acta Médica Colombiana. 2002;27(4):9.Google Scholar
  9. 9.
    Santos O, Gomez A, Vizcaino V, Casas MC, Ramirez MP, Olaya P. Genotipos circulantes del virus de la hepatitis C en Colombia. Biomedica. 2017;37(1):22–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Arroyave OJC, Alvarez C, Correa AG, Balcazar MN, Arbelaez MMP, Navas NMC. Infección por el virus de la hepatitis C en individuos transfundidos antes de 1994 en Antioquia, Colombia. Rev Colomb Gastroenterol. 2014;29(4):383–9.Google Scholar
  11. 11.
    Yepes IJ, Lince B, Caez C, de Vuono G. Factores de riesgo para la infección por el virus de la hepatitis C en la Costa Caribe colombiana: un estudio de casos y controles. Biomedica. 2016;36(4):564–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Sepulveda-Arias JC, Isaza C, Velez JP. Hepatitis B and C prevalence among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Pereira, Colombia. J Infect Dev Ctries. 2014;8(9):1228–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Tengan FM, Ibrahim KY, Dantas BP, Manchiero C, Magri MC, Bernardo WM. Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review. BMC Infect Dis. 2016;16(1):663.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Santos O, Londoño M, Marín J, Muñoz O, Mena Á, Guzmán C, et al. An experience of liver transplantation in Latin America: a medical center in Colombia. Colomb Med (Cali). 2015;46(1):8–13.Google Scholar
  16. 16.
    •• de la Hoz F. Epidemiología de la hepatitis C en Latinoamérica y Colombia. Biomedica. 2000;20(1):66–72. A very important document about available epidemiological data in different at risk populations Colombia.Google Scholar
  17. 17.
    Berbesi-Fernández D, Segura-Cardona Á, Montoya-Vélez L, Castaño-Perez GA. Hepatitis C and HIV in injecting drug users in Armenia, Colombia. Adicciones. 2015;27(4):246–52.CrossRefPubMedGoogle Scholar
  18. 18.
    • CDC. Testing recommendations for hepatitis C virus infection 2015 [updated October 15, 2015. Available from: An important update about screening and testing for hepatitis C.
  19. 19.
    Centers for Disease C, Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62(18):362–5.Google Scholar
  20. 20.
    Saludes V, Gonzalez V, Planas R, Matas L, Ausina V, Martro E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol. 2014;20(13):3431–42.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol. 2014;20(22):6701–6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    • van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93. An important article about outcomes after SVR is achieved.CrossRefPubMedGoogle Scholar
  23. 23.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–94.CrossRefGoogle Scholar
  24. 24.
    AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. [April, 2018].
  25. 25.
    •• Marin JI, Yepes I, Restrepo JC. Recomendaciones para el tratamiento de la infección crónica por el virus de la hepatitis C Genotipo 1 en Colombia. A very important document for recommendations of use of available DAAs in Colombia.
  26. 26.
    Colombia. Ministerio de Salud y Protección Social; Dirección de Medicamentos y Tecnologías en Salud & Colombia. Instituto de Evaluación Tecnológica en Salud. IETS; (2017). Vía clínica para el tratamiento de hepatitis C crónica: Versión completa. 66 p.
  27. 27.
    Colombia. Ministerio de Salud y Protección Social; Dirección de Medicamentos y Tecnologías en Salud. (2017). Estudios previos para la adquisición de medicamentos para el tratamiento del Virus de la Hepatitis C por intermedio del Fondo Rotatorio Regional.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Federico Hinestrosa
    • 1
    Email author
  • Juan Ignacio Marín
    • 2
  • Octavio Muñoz Maya
    • 2
  • Oscar Santos
    • 2
  • Juan Carlos Restrepo
    • 2
  1. 1.Orlando Immunology CenterUniversity of Central FloridaOrlandoUSA
  2. 2.Liver Transplant and Hepatology GroupHospital Pablo Tobón UribeMedellínColombia

Personalised recommendations